David E Elliott

US Patent:

6764838, Jul 20, 2004

Filed:

Dec 11, 1998

Appl. No.:

09/209732

Inventors:

Joel V. Weinstock - Iowa City IA
David E. Elliott - Iowa City IA

Assignee:

University of Iowa Research Foundation - Iowa City IA

International Classification:

C12P 2104

US Classification:

435 711, 435325, 4241841, 4242651, 424520, 530350, 530412, 530855

Abstract:

The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohns disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis and multiple sclerosis can be treated by the methods and compositions disclosed therein.

US Patent:

7250173, Jul 31, 2007

Filed:

Feb 13, 2004

Appl. No.:

10/779249

Inventors:

Joel V. Weinstock - Iowa City IA, US
David E. Elliott - North Liberty IA, US

Assignee:

University of Iowa Research Foundation - Iowa City IA

International Classification:

A61K 39/00
A61K 39/38
A61K 39/002
A61K 39/005
A61K 39/008

US Classification:

4242651, 4242691, 4241841

Abstract:

The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis and multiple sclerosis can be treated by the methods and compositions disclosed therein.

US Patent:

7833537, Nov 16, 2010

Filed:

Jul 30, 2007

Appl. No.:

11/888061

Inventors:

Joel V. Weinstock - Iowa City IA, US
David E. Elliott - Iowa City IA, US

Assignee:

University of Iowa Research Foundation - Iowa City IA

International Classification:

A61K 39/00
A61K 39/38
A61K 39/002
A01N 63/00
A01N 65/00

US Classification:

4242651, 4242691, 4241841, 424 931

Abstract:

The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis and multiple sclerosis can be treated by the methods and compositions disclosed therein.

US Patent:

20050118655, Jun 2, 2005

Filed:

Nov 17, 2003

Appl. No.:

10/715659

Inventors:

Joel Weinstock - Iowa City IA, US
David Elliott - Iowa City IA, US

International Classification:

A61K039/05
G01N033/53
G01N033/569

US Classification:

435007220, 424245100

Abstract:

The invention relates to a method of screening a heminthic parasite preparation that affects a regulatory T cell function and a method of treating a disease by altering a regulatory T cell activity through the administration of a parasite preparation.

US Patent:

20100303721, Dec 2, 2010

Filed:

Sep 19, 2008

Appl. No.:

12/234332

Inventors:

Joel V. Weinstock - Iowa City IA, US
David E. Elliott - Iowa City IA, US

Assignee:

University of Iowa, The Research Foundation - Iowa City IA

International Classification:

A61K 49/00
A61K 39/00
A61P 37/00
A61P 37/04
A61P 29/00
A61K 35/56
C12Q 1/02

US Classification:

424 91, 4242651, 424520, 435 29

Abstract:

The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis, multiple sclerosis, autoimmune thyroiditis, allergic rhinitis, colon polyps/colon cancer and asthma can be treated by the methods and compositions disclosed therein.

US Patent:

20160045581, Feb 18, 2016

Filed:

Apr 10, 2015

Appl. No.:

14/683778

Inventors:

- Iowa City IA, US
David E. Elliott - North Liberty IA, US
George J. Weiner - Iowa City IA, US

International Classification:

A61K 39/00
G01N 33/68
A61K 9/00

Abstract:

The invention relates to helminthic parasite preparations and their use for treatment or prevention of GVHD in a subject that has undergone a transplant. The invention also related to helminthic parasite preparations and their use for prevention of GVHD in a subject prior to a transplant.